全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
华西医学  2011 

磁共振动态增强扫描及弥散加权成像对肝癌肝动脉化学栓塞治疗的疗效判断

, PP. 1351-1355

Keywords: 肝肿瘤,化学栓塞,治疗,磁共振成像,扩散加权成像,动态增强扫描

Full-Text   Cite this paper   Add to My Lib

Abstract:

【】 目的 探讨磁共振动态增强扫描及磁共振弥散加权成像(diffusionweightedimaging,DWI)对肝癌经导管动脉内化学栓塞(transcatheterarterialchemoembolization,TACE)治疗后的肿瘤残余及复发的判断价值。 方法 2009年1月-2010年10月,对28例经证实的肝癌患者在TACE治疗前、治疗后3~7d及治疗后1~2个月、3~6个月行磁共振动态增强及DWI扫描,动态测量表观弥散系数(apparentdiffusioncoefficient,ADC)值,与数字减影血管造影(digitalsubstractionangiography,DSA)检查对照,评价动态增强扫描及DWI对肿瘤残留或复发的检出能力。〖HTH〗结果 对肿瘤残余及复发的显示,动态增强扫描灵敏度为90.0%,特异度为96.9%;DWI灵敏度为96.7%,特异度为93.8%;动态增强扫描与DWI相结合的灵感度为100.0%,特异度为99.5%;DSA灵敏度和特异度分别为96.7%、100.0%。TACE治疗前所有肿瘤实质的ADC值为(1.134±0.014)×10-3mm2/s;TACE治疗后3~7dADC值为(1.162±0.016)×10-3mm2/s;TACE治疗后1~2个月碘油沉积较好,无明显残余或复发病灶的ADC值为(1.175±0.015)×10-3mm2/s,3~6个月后随访病灶ADC值为(1.179±0.017)×10-3mm2/s;TACE治疗后1~2个月碘油沉积不完全或无明显沉积病灶ADC值为(1.147±0.016)×10-3mm2/s,3~6个月后随访病灶实质平均ADC值(1.142±0.012)×10-3mm2/s。 结论 将动脉增强扫描与DWI相结合可提高对TACE治疗后肝癌残余及复发判断的灵敏度及特异度;对肿瘤组织平均ADC值的动态测量、观察可及早判断肿瘤复发的可能性。【Abstract】 Objective Toevaluatethedynamiccontrast-enhancedMRIanddiffusionweightedimaging(DWI)injudgingtheremnantandrecurrenceonhepatocellularcarcinoma(HCC)aftertranscatheterarterialchemoembolization(TACE). Methods BetweenJanuary2009andOctober2010,28patientswithHCCunderwentdynamiccontrast-enhancedMRIandDWIbeforeandafterTACE3-7days,1-2monthsand3-6months,respectively,andtheapparentdiffusioncoefficient(ADC)valueofthetumorwerealsomeasuredatabovementionedtimepoints.Thesensitivityandspecificityofdynamiccontrast-enhancedMRIandDWIindiagnosisofresidualtumorandrecurrentcancerwasqualitativelyevaluatedbycomparingwiththeDSAresults. Results ComparedwithDSA,thesensitivityandspecificityofdynamiccontrast-enhancedMRIwere90.0%and96.9%byrevealingtheremnantandrecurrenceofHCC,whilethesensitivityandspecificityofDWIwere96.7%and93.8%respectively.Combiningdynamiccontrast-enhancedMRIandDWIthesensitivityandspecificitywereimprovedto100.0%and99.5%,respectively.ThemeanADCvalueoftumorbeforeandafter3-7daysofTACEwere(1.134±0.014)×10-3and(1.162±0.016)×10-3mm2/s,respectively.ThemeanADCvalueoftumorwithoutandwithremnantandrecurrenceafter1-2monthsand3-6monthsfollowupwere(1.175±0.015)×10-3,and(1.179±0.017)×10-3mm2/s;(1.147±0.016)×10-3and(1.142±0.012)×10-3mm2/s,respectively. Conclusions Combiningdynamiccontrast-enhancedMRIandDWIcouldimprovethesensitivityandspecificitytodetecttheremnantandrecurrenceofHCCafterTACE.MeasuringtheADCvalueduringfollowupofHCCpatientsafterTACEcouldpredicttheprobabilityoftumorrecurrence.

References

[1]   Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency[J]. Cardiovasc Intervent Radiol, 2003, 26(2): 111-117.
[2]   Geschwind JF, Artemov D, Abraham S, et al. Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis[J]. J Vasc Interv Radiol, 2000, 11(10): 1245-1255.
[3]   Chen CY, Li CW, Kuo YT, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience[J]. Radiolog, 2006, 239(2): 448-456.
[4]   Chung JC, Naik NK, Lewandowski RJ, et al. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization[J]. World J Gastroenterol, 2010, 16(25): 3161-3167.
[5]   Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment[J]. J Rheumatol, 2008, 35(5): 855-861.
[6]   Goshima S, Kanematsu M, Kondo H, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator [J]. J Magn Reson Imaging, 2008, 27(4): 834-839.
[7]   袁正, 董生, 许立超, 等. 磁共振扩散加权成像在肝癌化疗栓塞术后随访中的临床应用[J]. 临床放射学杂志, 2009, 28(6): 821-824.
[8]   尚全良, 肖恩华, 贺忠, 等. 肝癌经导管动脉灌注化疗栓塞术疗效的MR扩散加权成像动态研究[J]. 中华放射学杂志, 2006, 40(3): 235-240.
[9]   Castrucci M, Sironi S, De Cobelli F, et al. Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization[J]. Abdom Imaging, 1996, 21(6): 488-494.
[10]   Liapi E, Geschwind JF, Vossen JA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization[J]. AJR Am J Roentgenol, 2008, 190(1): 67-73.
[11]   Sturm JW, Keese MA, Bonninghoff RG, et al. Locally ablative therapies of hepatocellular carcinoma[J]. Onkologie, 2001, 24(Suppl 5): 35-45.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133